Free EU-Wide Shipping on Orders Over €200
This product is intended solely for use as a research chemical in vitro and laboratory experimentation by licensed, qualified professionals.
Thymosin Alpha-1
59,99 €
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue. Researched for immune modulation, T-cell maturation, and antiviral properties. 5mg lyophilized powder, ≥99% purity.
Bulk Discounts
- Buy 3+ for 56,99 € each and save 5%
- Buy 5+ for 53,99 € each and save 10%
- Buy 10+ for 50,99 € each and save 15%
Ships Tomorrow - order cutoff passed
Free EU Shipping on orders over €200
Third party tested
Thymosin Alpha-1—
59,99 €
Advanced Laboratory Testing
HPLC
Mass Spec
≥99% Purity
Secure
Fast Ship
EU Based
Characteristics
| Molecular Formula | C129H215N33O55 |
| CAS | 62304-98-7 |
| Molar Mass | 3108.28 g/mol |
| Amino Acid Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn |
| Synonyms | Tα1, Thymalfasin, Zadaxin |
| Solubility | Soluble in water |
| Organoleptic Profile | White powder |
| Physical Form | Lyophilized powder |
How does Thymosin Alpha-1 work?
Thymosin Alpha-1 is a 28-amino acid peptide first isolated from Thymosin Fraction 5 by Allan Goldstein in 1977. It plays a central role in T-cell development and immune regulation.
The peptide activates dendritic cells and enhances T-cell differentiation, particularly of CD4+ and CD8+ subsets. It stimulates natural killer (NK) cell activity and modulates cytokine production, shifting immune responses toward a Th1 phenotype.
Thymosin Alpha-1 acts on Toll-like receptors (TLR2, TLR9) to enhance both innate and adaptive immunity. Its immunomodulatory properties are distinct from immunosuppressants — it restores immune balance rather than broadly suppressing immune function.
Benefits
- Immune Modulation: Enhances T-cell differentiation and restores immune balance through Th1/Th2 regulation
- Antiviral Properties: Augments immune response against viral infections including hepatitis B and C
- NK Cell Activation: Stimulates natural killer cell activity and enhances innate immune surveillance
- Dendritic Cell Maturation: Activates dendritic cells and promotes antigen presentation
- Vaccine Adjuvant: Enhances vaccine efficacy in immunocompromised research models
Side Effects
Thymosin Alpha-1 is generally considered safe and well tolerated when used in research settings. However, as with any substance, there is a potential for side effects, particularly when used at high concentrations or for prolonged periods.
- Injection Site Reactions: Mild redness or discomfort at the injection site
- Flu-Like Symptoms: Transient mild flu-like symptoms including low-grade fever
- Fatigue: Temporary fatigue during initial administration periods
- Well-Tolerated: Generally well-tolerated in clinical trials with a favorable safety profile
It's important to note that the safety and efficacy of Thymosin Alpha-1 for human use have not been fully established, and more research is needed to determine the long-term effects of this peptide complex.
Summary
Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue (Thymosin Fraction 5) by Dr. Allan Goldstein at the George Washington University in 1977.
A synthetic version (thymalfasin, brand name Zadaxin) has been approved in over 35 countries for treatment of hepatitis B, hepatitis C, and as an immune adjuvant. It has been studied in over 4,400 patients across clinical trials.
Certificate of Analysis (COA) available upon request. Each batch is tested via HPLC for purity and Mass Spectrometry for identity confirmation.
References
- 1Goldstein AL, et al. "Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide" Proceedings of the National Academy of Sciences. 1977. doi:10.1073/pnas.74.2.725
- 2Garaci E, et al. "Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application" International Journal of Immunopharmacology. 2000. doi:10.1016/S0192-0561(00)00058-3
- 3Tuthill C, et al. "Thymalfasin: biological properties and clinical applications" International Immunopharmacology. 2020. doi:10.1016/j.intimp.2020.107104
Resource
All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration or the European Medicines Agency. Products are not intended to diagnose, treat, cure, or prevent any disease.